Nathan D Seligson
Overview
Explore the profile of Nathan D Seligson including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
29
Citations
324
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Thomas M, Li J, King K, Persaud A, Duah E, VanGundy Z, et al.
Haematologica
. 2023 Mar;
108(8):2155-2166.
PMID: 36861411
Multiple Myeloma (MM) is an incurable plasma cell malignancy often treated by autologous stem cell transplant (ASCT). Clinical response to ASCT has been associated with DNA repair efficiency. Here we...
12.
Busaidy N, Konda B, Wei L, Wirth L, Devine C, Daniels G, et al.
Thyroid
. 2022 Jun;
32(10):1184-1192.
PMID: 35658604
Oncogenic BRAF mutations are commonly found in advanced differentiated thyroid cancer (DTC), and reports have shown efficacy of BRAF inhibitors in these tumors. We investigated the difference in response between...
13.
King K, Davis H, Moorman-Li R, Cook K, Seligson N
Pharmacy (Basel)
. 2022 Jun;
10(3).
PMID: 35645326
Community service serves as a major aspect of pharmacy education; however, coronavirus disease 2019 (COVID-19) represented a significant disruption to student involvement. The College of Pharmacy student council, which serves...
14.
Seligson N, Tang J, Jin D, Bennett M, Elvin J, Graim K, et al.
NPJ Precis Oncol
. 2022 Apr;
6(1):29.
PMID: 35468996
Leiomyosarcoma (LMS) is a rare, aggressive, mesenchymal tumor. Subsets of LMS have been identified to harbor genomic alterations associated with homologous recombination deficiency (HRD); particularly alterations in BRCA2. Whereas genomic...
15.
Hsu J, Seligson N, Hays J, Miles W, Chen J
JCO Precis Oncol
. 2022 Feb;
6:e2100211.
PMID: 35108033
Purpose: Soft tissue and bone sarcomas are rare malignancies that exhibit significant pathologic and molecular heterogeneity. Deregulation of the CDKN2A-CCND-CDK4/6-retinoblastoma 1 (Rb) pathway is frequently observed in about 25% of...
16.
Cook K, Duong B, Seligson N, Arn P, Funanage V, Gripp K, et al.
Clin Pharmacol Ther
. 2021 Jul;
110(3):555-558.
PMID: 34254671
No abstract available.
17.
Seligson N, Maradiaga R, Stets C, Katzenstein H, Millis S, Rogers A, et al.
NPJ Precis Oncol
. 2021 May;
5(1):43.
PMID: 34021224
Sarcomas harboring EWSR1-NFATc2 fusions have historically been categorized and treated as Ewing sarcoma. Emerging evidence suggests unique molecular characteristics and chemotherapy sensitivities in EWSR1-NFATc2 fusion positive sarcomas. Comprehensive genomic profiles...
18.
Nelson R, Seligson N, Bottiglieri S, Carballido E, Cueto A, Imanirad I, et al.
Cancers (Basel)
. 2021 Apr;
13(7).
PMID: 33805415
Multi-gene assays often include and, in certain instances, may report associated toxicity risks for irinotecan, belinostat, pazopanib, and nilotinib. However, guidance for incorporating results into therapeutic decision-making is mostly lacking...
19.
Turner S, Seligson N, Parag B, Shea K, Hobbs A
Am J Health Syst Pharm
. 2021 Mar;
78(Supplement_2):S57-S61.
PMID: 33788910
Purpose: Previous studies indicate that the polymerase chain reaction (PCR) nasal assay for methicillin-resistant Staphylococcus aureus (MRSA) has a consistently high (>95%) negative predictive value (NPV) in ruling out MRSA...
20.
Apple J, Guerci J, Seligson N, Curtis S
Am J Health Syst Pharm
. 2020 Nov;
78(1):18-21.
PMID: 33155021
No abstract available.